Sign in
4

Changes in Ownership

Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-011461

Chief Medical Officer sold 49,579 shares at an average $30.54 ($1,513,942)

  • Chief Medical Officer acquired 49,579 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Yeramian Patrick D Chief Medical Officer 2023-04-17 Option exercise 10b5-1 +44,861 $0.37 $16,599 253,278 D: show line 1 in the form
Yeramian Patrick D Chief Medical Officer 2023-04-17 Option exercise 10b5-1 +4,718 $6.88 $32,460 257,996 D: show line 2 in the form
Yeramian Patrick D Chief Medical Officer 2023-04-17 Sale 10b5-1 −49,279 $30.53 $1,504,660 208,717 D: show line 3 in the form
Yeramian Patrick D Chief Medical Officer 2023-04-17 Sale 10b5-1 −300 $30.94 $9,282 208,417 D: show line 4 in the form
Open-market sales · 49,579 sh · avg $30.54 · $1,513,942

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Yeramian Patrick D Chief Medical Officer 2023-04-17 Option exercise · Stock Option (right to buy) 10b5-1 −44,861 17,605 D: show line 5 in the form
Yeramian Patrick D Chief Medical Officer 2023-04-17 Option exercise · Stock Option (right to buy) 10b5-1 −4,718 43,534 D: show line 6 in the form
Loading xslF345X04/doc4.xml…